Analysis of rocuronium in human plasma by liquid chromatography-tandem mass spectrometry with application in clinical pharmacokinetics

Página do item simplificado
dc.contributor.authorMoraes, Natália Valadares de [UNESP]
dc.contributor.authorLauretti, Gabriela Rocha
dc.contributor.authorOliveira Filgueira, Gabriela Campos de
dc.contributor.authorPortes Lopes, Bruno Carvalho
dc.contributor.authorLanchote, Vera Lucia
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.date.accessioned2014-12-03T13:11:44Z
dc.date.available2014-12-03T13:11:44Z
dc.date.issued2014-03-05
dc.description.abstractRocuronium (ROC) is a neuromuscular blocking agent used in surgical procedures which is eliminated primarily by biliary excretion. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for analysis of ROC in human plasma. Separation of ROC and IS (verapamil) was performed using an endcapped C-18 column and a mixture of water:acetonitrile:trifluoracetic acid (50:50:0.1, v/v) as mobile phase. Aliquots of 100 mu L of human plasma were extracted at pH 3, using dichloromethane. The lower limit of quantification of 5 ng/mL shows the high sensitivity of this method. Intra- and inter-assay precision (as relative standard deviation) was all <= 14.2% and accuracy (as relative standard error) did not exceed 10.1%. The validated method was successfully applied to quantify ROC concentrations in patients under surgical procedures up to 6 h after the administration of the 0.4-0.9 mg/kg ROC. The pharmacokinetic parameter estimations of ROC showed AUC/dose of 563 mu g min/mL, total clearance of 2.5 mL/min/kg, volume of distribution at steady state of 190 mL/kg and mean residence time of 83 min. (C) 2013 Elsevier B.V. All rights reserved.en
dc.description.affiliationUniv Estadual Paulista, Fac Ciencias Farmaceut, Dept Principios Ativos Nat & Toxicol, BR-14801902 Araraquara, SP, Brazil
dc.description.affiliationUniv Sao Paulo, Fac Med Ribeirao Preto, Dept Biomecan Med & Reabilitado Sistema Locomotor, BR-14049900 Ribeirao Preto, SP, Brazil
dc.description.affiliationUniv Sao Paulo, Fac Med Ribeirao Preto, Dept Obstet & Ginecol, BR-14049900 Ribeirao Preto, SP, Brazil
dc.description.affiliationUniv Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Analises Clin Toxicol & Bromatol, BR-14040903 Ribeirao Preto, SP, Brazil
dc.description.affiliationUnespUniv Estadual Paulista, Fac Ciencias Farmaceut, Dept Principios Ativos Nat & Toxicol, BR-14801902 Araraquara, SP, Brazil
dc.format.extent180-185
dc.identifierhttp://dx.doi.org/10.1016/j.jpba.2013.11.032
dc.identifier.citationJournal Of Pharmaceutical And Biomedical Analysis. Amsterdam: Elsevier Science Bv, v. 90, p. 180-185, 2014.
dc.identifier.doi10.1016/j.jpba.2013.11.032
dc.identifier.issn0731-7085
dc.identifier.lattes8087835756545728
dc.identifier.urihttp://hdl.handle.net/11449/113483
dc.identifier.wosWOS:000331854600023
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofJournal of Pharmaceutical and Biomedical Analysis
dc.relation.ispartofjcr2.831
dc.relation.ispartofsjr0,919
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.subjectRocuroniumen
dc.subjectLC-MS/MSen
dc.subjectHuman plasmaen
dc.subjectPharmacokineticsen
dc.titleAnalysis of rocuronium in human plasma by liquid chromatography-tandem mass spectrometry with application in clinical pharmacokineticsen
dc.typeArtigo
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dcterms.rightsHolderElsevier B.V.
unesp.author.lattes8087835756545728
unesp.author.orcid0000-0002-0074-4953[5]
unesp.author.orcid0000-0001-7499-5942[3]
unesp.author.orcid0000-0002-4389-058X[1]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Ciências Farmacêuticas, Araraquarapt

Arquivos

Coleções

Artigos - Princípios Ativos Naturais e Toxicologia - FCFAR